Laboratory measurement of the direct oral anticoagulants

被引：80

作者：

Dale, Brian J. ^{[1
]}

Chan, Noel C. ^{[2
]}

Eikelboom, John W. ^{[2
,3
,4
]}

机构：

[1] Univ S Australia, Sch Pharm & Med Sci, GPO Box 2471, Adelaide, SA 5001, Australia

[2] McMaster Univ, Populat Hlth Res Inst, Hamilton, ON, Canada

[3] McMaster Univ, Dept Med, Hamilton, ON, Canada

[4] Thrombosis & Atherosclerosis Res Inst, Hamilton, ON, Canada

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2016年 / 172卷 / 03期

关键词：

anticoagulants; coagulation; drugs; laboratory haematology; thrombosis; FACTOR XA INHIBITOR; DIRECT THROMBIN INHIBITOR; PARTIAL THROMBOPLASTIN TIME; MONITORING UNFRACTIONATED HEPARIN; INTERNATIONAL NORMALIZED RATIO; IN-VITRO; COAGULATION ASSAYS; PROTHROMBIN TIME; ANTI-XA; PLASMA-CONCENTRATIONS;

D O I：

10.1111/bjh.13810

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Direct oral anticoagulants (DOACs), including the direct thrombin inhibitor, dabigatran, and the direct factor Xa (FXa) inhibitors, rivaroxaban, apixaban and edoxaban, are approved for thromboembolism prevention and treatment. These drugs do not require routine coagulation monitoring but, in some circumstances, measurement of drug level or anticoagulant effect may be necessary. Although traditional coagulation tests lack analytical sensitivity and specificity, they are widely available and inexpensive, and can provide useful information regarding the residual anticoagulant effect of DOACs. Hemoclot((R)) and ecarin-based assays can be used to quantify dabigatran level and calibrated chromogenic anti-FXa assays are suitable for measuring rivaroxaban, apixaban and edoxaban levels, but these tests are not yet widely available.

引用

页码：315 / 336

页数：22

共 91 条

[11] The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans [J].

Blech, Stefan ;

Ebner, Thomas ;

Ludwig-Schwellinger, Eva ;

Stangier, Joachim ;

Roth, Willy .

DRUG METABOLISM AND DISPOSITION, 2008, 36 (02) :386-399

[12] Thrombin functions during tissue factor-induced blood coagulation [J].

Brummel, KE ;

Paradis, SG ;

Butenas, S ;

Mann, KG .

BLOOD, 2002, 100 (01) :148-152

[13] Prothrombinase-induced clotting time assay for determination of the anticoagulant effects of unfractionated and low-molecular-weight heparins, fondaparinux, and thrombin inhibitors [J].

Calatzis, Andreas ;

Peetz, Dirk ;

Haas, Sylvia ;

Spannagl, Michael ;

Rudin, Karin ;

Wilmer, Marianne .

AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2008, 130 (03) :446-454

[14] Laboratory measurement of the anticoagulant activity of edoxaban: a systematic review [J].

Cuker, Adam ;

Husseinzadeh, Holleh .

JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2015, 39 (03) :288-294

[15] Laboratory Measurement of the Anticoagulant Activity of the Non-Vitamin K Oral Anticoagulants [J].

Cuker, Adam ;

Siegal, Deborah M. ;

Crowther, Mark A. ;

Garcia, David A. .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2014, 64 (11) :1128-1139

[16] Dabigatran Effects on the International Normalized Ratio, Activated Partial Thromboplastin Time, Thrombin Time, and Fibrinogen: A Multicenter, In Vitro Study [J].

Dager, William E. ;

Gosselin, Robert C. ;

Kitchen, Steve ;

Dwyre, Dennis .

ANNALS OF PHARMACOTHERAPY, 2012, 46 (12) :1627-1636

[17] Comparison of the effects of apixaban and rivaroxaban on prothrombin and activated partial thromboplastin times using various reagents [J].

Dale, B. J. ;

Ginsberg, J. S. ;

Johnston, M. ;

Hirsh, J. ;

Weitz, J. I. ;

Eikelboom, J. W. .

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2014, 12 (11) :1810-1815

[18] Dabigatran attenuates thrombin generation to a lesser extent than warfarin: could this explain their differential effects on intracranial hemorrhage and myocardial infarction? [J].

Dale, Brian ;

Eikelboom, John W. ;

Weitz, Jeffrey I. ;

Young, Ed ;

Paikin, Jeremy S. ;

Coppens, Michiel ;

Whitlock, Richard P. ;

Connolly, Stuart J. ;

Ginsberg, Jeffrey S. ;

Hirsh, Jack .

JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2013, 35 (02) :295-301

[19] The ex vivo reversibility of dabigatran-induced whole-blood coagulopathy as monitored by thromboelastography: Mechanistic implications for clinical medicine [J].

Davis, Patrick K. ;

Musunuru, Harsha ;

Walsh, Mark ;

Mitra, Raman ;

Ploplis, Victoria ;

Castellino, Francis J. .

THROMBOSIS AND HAEMOSTASIS, 2012, 108 (03) :586-588

[20] Rapid determination of apixaban concentration in human plasma by liquid chromatography/tandem mass spectrometry: Application to pharmacokinetic study [J].

Delavenne, Xavier ;

Mismetti, Patrick ;

Basset, Thierry .

JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2013, 78-79 :150-153

← 1 2 3 4 5 6 7 8 9 10 →